Enhancing Use of Hydroxyurea In Sickle Cell Disease Using Patient Navigators

NACompletedINTERVENTIONAL
Enrollment

353

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

July 7, 2018

Study Completion Date

December 31, 2018

Conditions
Sickle Cell Disease
Interventions
BEHAVIORAL

Patient Navigator

A specially trained (SCD knowledgable) Patient Navigator will act as a liaison who assists participants in increasing adherence to HU through disease education, addressing barriers to care and improving adherence to HU. PN utilize various techniques geared toward the individual patients needs. Interventions utilized by a PN include improving disease management skills, educational materials about disease, HU adherence, motivational interviewing, care coordination and social support.

BEHAVIORAL

Recruitment into Specialty Care

A specially trained (SCD knowledgeable) Patient Navigator will act as a liaison to participants in increasing adherence to Hydroxyurea. Interventions utilized by a PN include teaching disease management skills, addressing barriers to care, disease education, HU management, motivational interviewing, care coordination and social support.

Trial Locations (1)

23298

Virginia Commonwealth University, Richmond

All Listed Sponsors
collaborator

Eastern Virginia Medical School

OTHER

collaborator

Children's Hospital of The King's Daughters

OTHER

collaborator

Virginia Department of Health

OTHER_GOV

collaborator

James Madison University

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Virginia Commonwealth University

OTHER

NCT02197845 - Enhancing Use of Hydroxyurea In Sickle Cell Disease Using Patient Navigators | Biotech Hunter | Biotech Hunter